SWKH News and Press, SWK Holdings Corporation From 03/07/22

Enteris BioPharma, a unit of SWK Holdings (NASDAQ:SWKH), announced the publication of a new white paper titled 'HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity.' The paper, co-authored by Thomas Daggs, vice president of product development & quality c...

Enteris BioPharma Publishes White Paper on Best Practices for Ensuring Content Uniformity in Solid Oral Dosage Manufacturing with HPAPI Paper examines barriers to achieving optimal content uniformity with HPAPIs and the techniques manufacturers should use with low-dose drug prod...

Enteris BioPharma to Participate in DCAT® Week 2022 PR Newswire BOONTON, N.J. , March 2, 2022 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a whol...

SWK Holdings Announces Reconstitution of Board of Directors with New Appointments PR Newswire DALLAS , Feb. 16, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized co...

Enteris BioPharma Highlights Progress in Oral Feasibility Program Six feasibility programs underway for oral tablet formulations developed with Enteris' Peptelligence® and ProPerma® technology platforms PR Newswire BOONTON, N.J. , Feb. 15, 2022 /PRN...

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Enteris BioPharma Launches Enhanced Website Showcasing Full Suite of Bench to Market™ Services PR Newswire BOONTON, N.J. , Jan. 10, 2022 /PRNewswire/ -- Enteris BioPharma, Inc. , a biotechnology company developing innovative drug products based on its ...

Special Committee Concludes Review of Non-Binding Proposal from Carlson Capital PR Newswire DALLAS , Jan. 5, 2022 /PRNewswire/ --SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") today announced that the special committee of the Company's board...

Enteris BioPharma Highlights 2021 Achievements and 2022 Outlook Enteris continues to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma® platforms -- Received two milestone payments totaling $15 million from Cara Therapeutics ...

Biotricity (BTCY +7.3%) is trading higher after the company announced the completion of a $12M non-convertible debt financing provided by SWK Funding LLC (NASDAQ:SWKH). Per the contractual terms, the health tech company will have an initial interest-only period of two years extendable to thre...